Full history for every metric is available with a Kvantra account
Surmodics, Inc. (SRDX)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 100 | 95 | 105 | 100 | 133 | 126 | 121 |
| Operating profit | $m | -6 | -12 | |||||
| Net profit | $m | 8 | 1 | 4 | -27 | -2 | -12 | -18 |
| EPS reported | $ | -0.82 | -1.23 | |||||
| Operating cashflow per share | $ | 0.02 | 0.16 | |||||
| Capex per share | $ | 0.25 | 0.06 | |||||
| FCF per share | $ | -0.23 | 0.11 | |||||
| Free cash flow | $m | -3 | -4 | |||||
| Net debt | $m | -11 | -0 | |||||
| Book value equity | $m | 119 | 111 | |||||
| Book value per share | $ | 8.40 | 7.79 | |||||
| Number of shares | m | 14.15 | 14.28 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 4.62 | 5.52 | |||||
| P/S LTM | x | 4.35 | 5.09 | |||||
| P/FCF LTM | x | -169.19 | -173.30 | |||||
| EV/EBITDA LTM | x | 115.48 | -74.66 | |||||
| EV/Sales LTM | x | 4.33 | 5.09 | |||||
| Earnings Yield LTM | % | -2.10% | -1.72% | |||||
| FCF Yield | % | -0.59% | -0.58% | |||||
| Quality | ||||||||
| ROE | % | -9.71% | -9.50% | |||||
| ROIC | % | -3.55% | -6.06% | |||||
| Operating margin | % | -4.48% | -16.05% | |||||
| Gross margin | % | 73.81% | 71.54% | |||||
| FCF/Sales | % | -2.57% | 2.66% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -4.91% | -0.02% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.10 | -0.11 | |||||
| Net Debt/EBITDA | x | -0.61 | -0.68 | |||||
| EBIT/Net interest | x | -1.59 | -5.38 | |||||
| Net debt/market cap | % | -1.92% | -0.02% | |||||
| Net debt/Equity | x | -0.09 | -0.00 | |||||
| Gross debt/equity | x | 0.28 | 0.29 | |||||
Company overview
Surmodics, Inc., together with its affiliates, specializes in providing advanced surface modification solutions tailored for intravascular medical devices. Additionally, the company supplies specialized chemical components essential for in vitro diagnostic immunoassay tests and microarrays. Its operations span both the United States and international markets. The company is structured into two primary divisions: Medical Device and In Vitro Diagnostics (IVD). Within the Medical Device segment, Surmodics offers innovative coating technologies that are engineered to improve the accessibility, maneuverability, and reliable deployment of medical devices. This segment also develops drug-delivery coating systems, enabling precise, localized therapeutic release directly from a device's surface for applications in various areas, including coronary, peripheral, neuro-vascular, and structural heart procedures. Moreover, this division is involved in the design, development, and manufacturing of interventional medical instruments, notably balloons and catheters, including drug-coated balloons utilized in the treatment of peripheral arterial disease and other conditions. The IVD segment focuses on creating and producing foundational component products and technologies for diagnostic immunoassay, molecular testing, and biomedical research. Its portfolio in this area includes protein stabilization reagents, specialized substrates, surface coatings, and antigens. Surmodics was established in 1979 and maintains its corporate headquarters in Eden Prairie, Minnesota.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Surmodics, Inc. (SRDX)
Surmodics, Inc., together with its affiliates, specializes in providing advanced surface modification solutions tailored for intravascular medical devices. Additionally, the company supplies specialized chemical components essential for in vitro diagnostic immunoassay tests and microarrays. Its operations span both the United States and international markets. The company is structured into two primary divisions: Medical Device and In Vitro Diagnostics (IVD). Within the Medical Device segment, Surmodics offers innovative coating technologies that are engineered to improve the accessibility, maneuverability, and reliable deployment of medical devices. This segment also develops drug-delivery coating systems, enabling precise, localized therapeutic release directly from a device's surface for applications in various areas, including coronary, peripheral, neuro-vascular, and structural heart procedures. Moreover, this division is involved in the design, development, and manufacturing of interventional medical instruments, notably balloons and catheters, including drug-coated balloons utilized in the treatment of peripheral arterial disease and other conditions. The IVD segment focuses on creating and producing foundational component products and technologies for diagnostic immunoassay, molecular testing, and biomedical research. Its portfolio in this area includes protein stabilization reagents, specialized substrates, surface coatings, and antigens. Surmodics was established in 1979 and maintains its corporate headquarters in Eden Prairie, Minnesota.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free